The novel beta2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells
Journal article published in 2015 by
M. Kraus,
J. Bader,
P. P. Geurink,
E. S. Weyburne,
A. C. Mirabella,
T. Silzle,
T. B. Shabaneh,
W. A. van der Linden,
Bruin G. De,
Haile,
Rooden E. Van,
C. Appenzeller,
N. Li,
A. F. Kisselev,
H. Overkleeft 
and other authors.
and other authors.
